Stay updated with breaking news from Nasdaq Nrix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nurix Therapeutics (NASDAQ:NRIX – Get Rating) issued its earnings results on Thursday. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07), MarketWatch Earnings reports. Nurix Therapeutics had a negative return on equity of 36.42% and a negative net margin of 394.21%. NRIX traded up $1.56 during trading on […]
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) were up 6.3% during mid-day trading on Friday . The stock traded as high as $14.15 and last traded at $14.10. Approximately 4,353 shares were traded during trading, a decline of 99% from the average daily volume of 581,968 shares. The stock had previously closed at […]
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) have earned a consensus rating of “Buy” from the eight research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price […]
U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948 crosses the...
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European...